Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects

@article{Eerenberg2011ReversalOR,
  title={Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects},
  author={E. Eerenberg and P. Kamphuisen and M. Sijpkens and J. Meijers and H. Buller and M. Levi},
  journal={Circulation},
  year={2011},
  volume={124},
  pages={1573–1579}
}
  • E. Eerenberg, P. Kamphuisen, +3 authors M. Levi
  • Published 2011
  • Medicine
  • Circulation
    • Background— Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of an antidote in case of serious bleeding or when an emergency intervention needs immediate correction of coagulation. This study evaluated the potential of prothrombin complex concentrate (PCC… CONTINUE READING
    View on Wolters Kluwer
    ahajournals.org
    1,328 Citations
    Highly Influential Citations
    36
    Background Citations
    282
    Methods Citations
    33
    Results Citations
    20
    1,328 Citations
    Citation Type

    Citation Type

    Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
    • 518
    • Highly Influenced
    • PDF
    Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    • 90
    Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
    • 33
    Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model.
    • 14
    Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model
    • 195
    • PDF
    More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
    • 32
    • PDF
    Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model
    • 33
    Reversal of novel oral anticoagulants in patients with major bleeding
    • 83
    • Highly Influenced
    Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate
    • 201
    • PDF
    Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model
    • 88

    References

    SHOWING 1-10 OF 36 REFERENCES
    Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
    • 1,312
    • PDF
    Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers
    • 295
    • PDF
    Oral rivaroxaban for symptomatic venous thromboembolism.
    • 1,981
    • PDF
    Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature
    • 333
    • PDF
    Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
    • 1,998
    • PDF
    Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity 1
    • 130
    Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement
    • 268
    Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate
    • 596
    Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
    • 91
    Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
    • 134